We are live on ! Find out more
SC

Stempoint Capital Portfolio holdings

AUM $522M
1-Year Est. Return 281.95%
This Fund
S&P 500
This Quarter Est. Return
+5.16%
1 Year Est. Return
+281.95%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$401M
AUM Growth
+$66.6M
Cap. Flow
+$201M
Cap. Flow %
50.06%
Top 10 Hldgs %
50.8%
Holding
80
New
26
Increased
21
Reduced
6
Closed
26

Top Buys

Rank Stock Value
1
SNDX icon
Syndax Pharmaceuticals
SNDX
+$19.5M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$15.5M
3
NUVL
Nuvalent
NUVL
+$13.6M
4
IMVT icon
Immunovant
IMVT
+$12.7M
5
ALKS icon
Alkermes
ALKS
+$10.6M

Top Sells

Rank Stock Value
1
FOLD
Amicus Therapeutics
FOLD
+$15.8M
2
ARQT icon
Arcutis Biotherapeutics
ARQT
+$14M
3
APLT
Applied Therapeutics
APLT
+$13.2M
4
AUTL
Autolus Therapeutics
AUTL
+$9.5M
5
DAWN
Day One Biopharmaceuticals
DAWN
+$7.06M

Sector Composition

Rank Sector Weight
1 Healthcare 99.15%
2 Financials 0.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
51
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$774B
$414K 0.1%
+85,000
New +$50.1M
SRRK icon
52
CALL
Scholar Rock
SRRK
$6.33B
$228K 0.06%
+100,000
New +$3.26M
HIMS icon
53
CALL
Hims & Hers Health
HIMS
$7.6B
$75K 0.02%
+75,000
New +$1.86M
SNDX icon
54
CALL
Syndax Pharmaceuticals
SNDX
$2.02B
$51K 0.01%
234,100
+4,100
+2% +$70.2K
ACLX
55
DELISTED
Arcellx
ACLX
– –
-60,076
Closed -$5.02M
APLT
56
CALL
DELISTED
Applied Therapeutics
APLT
– –
-251,600
Closed -$75.5K
APLT
57
DELISTED
Applied Therapeutics
APLT
– –
-1,554,586
Closed -$13.2M
ATXS
58
DELISTED
Astria Therapeutics
ATXS
– –
-56,287
Closed -$619K
AUTL
59
Autolus Therapeutics
AUTL
$383M
– –
-2,616,602
Closed -$9.5M
BBIO icon
60
BridgeBio Pharma
BBIO
$15.9B
– –
-94,885
Closed -$2.42M
CABA icon
61
Cabaletta Bio
CABA
$461M
– –
-1,278,444
Closed -$6.03M
CAPR icon
62
Capricor Therapeutics
CAPR
$1.13B
– –
-93,638
Closed -$1.42M
CATX icon
63
Perspective Therapeutics
CATX
$341M
– –
-238,084
Closed -$3.18M
DAWN
64
DELISTED
Day One Biopharmaceuticals
DAWN
– –
-506,978
Closed -$7.06M
FOLD
65
DELISTED
Amicus Therapeutics
FOLD
– –
-1,481,809
Closed -$15.8M
IDYA icon
66
IDEAYA Biosciences
IDYA
$3.47B
– –
-132,703
Closed -$4.2M
IMTX icon
67
Immatics
IMTX
$1.31B
– –
-449,735
Closed -$5.13M
IMVT icon
68
CALL
Immunovant
IMVT
$8.27B
– –
-200,000
Closed -$113K
KROS icon
69
Keros Therapeutics
KROS
$211M
– –
-86,930
Closed -$5.05M
NGNE icon
70
Neurogene
NGNE
$744M
– –
-73,299
Closed -$3.08M
NRIX icon
71
Nurix Therapeutics
NRIX
$2.4B
– –
-203,015
Closed -$4.56M
PYXS icon
72
Pyxis Oncology
PYXS
$150M
– –
-850,210
Closed -$3.12M
SLNO
73
DELISTED
Soleno Therapeutics
SLNO
– –
-123,177
Closed -$6.22M
SRPT icon
74
Sarepta Therapeutics
SRPT
$1.82B
– –
-15,014
Closed -$1.88M
TCRX icon
75
TScan Therapeutics
TCRX
$59.8M
– –
-860,951
Closed -$4.29M
1 2
3
4

Similar funds

JE
JMAC Enterprises Newtown, Pennsylvania $522M AUM 15.34% 1-Year Est. Return
GS
GWN Securities Palm Beach Gardens, Florida $523M AUM 20.1% 1-Year Est. Return
LT
Legacy Trust Grand Rapids, Michigan $522M AUM 23.56% 1-Year Est. Return
WFA
WestHill Financial Advisors San Rafael, California $523M AUM 15.95% 1-Year Est. Return
TCM
TruNorth Capital Management Kalamazoo, Michigan $522M AUM 14.26% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
ETS
ESL Trust Services Rochester, New York $524M AUM 17.18% 1-Year Est. Return
CM
Conifer Management New York $524M AUM 14.11% 1-Year Est. Return

Stempoint Capital's Q4 2024 Portfolio in Review

As of Q4 2024, Stempoint Capital held 80 positions worth $401M, up 20% from $334M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Stempoint Capital deployed $201M of net new capital in Q4 2024, opening 26 new positions and adding to 21 existing holdings. Its largest new stake was Xenon Pharmaceuticals: 375,845 shares worth $14.7M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Arcutis Biotherapeutics, an estimated $14M trimmed.

  • Stempoint Capital's largest Q4 2024 buy was Xenon Pharmaceuticals: 375,845 shares worth $14.7M.
  • Stempoint Capital added most to Syndax Pharmaceuticals in Q4 2024, an estimated $19.5M increase.
  • Stempoint Capital's biggest Q4 2024 reduction was Arcutis Biotherapeutics, cutting an estimated $14M.
  • Stempoint Capital fully exited Amicus Therapeutics in Q4 2024, selling an estimated $15.8M.
  • Stempoint Capital's ten largest holdings make up 51% of its $401M portfolio in Q4 2024.
  • Stempoint Capital opened 26 new positions and closed 26 in Q4 2024.
  • Stempoint Capital's portfolio value rose 20% quarter-over-quarter to $401M.

Based on Stempoint Capital's 13F filing for Q4 2024, filed 14 Feb 2025.